{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T02:32:20Z","timestamp":1794277940721,"version":"4.9.0"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":577,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2014,2]]},"abstract":"<jats:sec>\n            <jats:title\/>\n            <jats:p>\n                                 <jats:bold>Reactivity and titers of autoantibodies vary during the course of autoimmune hepatitis (AIH), and some autoantibodies have been associated with disease activity and adverse outcomes after treatment. The aim of this study was to assess the autoantibody behavior in AIH and its significance as predictors of biochemical and histological remission. A total of 117 patients with AIH (mean age 18.6 [4\u201369] years) were evaluated and tested for autoantibodies at disease onset and successively (mean 3.2 [2\u20136] times) after a mean follow-up evaluation of 70 [20\u2013185] months. Antismooth muscle (ASMA), antiliver kidney microsome type 1 (anti-LKM1), antiliver cytosol type 1 (anti-LC1), antimitochondrial, antinuclear (ANA), and antiactin antibodies (AAA) were determined at disease onset and 379 other times during the follow-up evaluation through indirect immunofluorescence in rodent tissues, HEp-2 cells, and human fibroblasts. Anti-SLA\/LP were assessed 45 times in the follow-up evaluation of 19 patients using enzyme-linked immunosorbent assay (ELISA). Upon admission, AIH types 1 and 2 were observed in 95 and 17 patients, respectively. Five subjects had AIH with anti-SLA\/LP as the sole markers. Patients initially negative for AAA did not develop these antibodies thereafter. ANA were detected<\/jats:bold>\n                                 <jats:bold>\n                                    de novo\n                                 <\/jats:bold>\n                                 <jats:bold>in six and three subjects with AIH types 1 and 2, respectively. After treatment, only ASMA (&gt;1:80) and AAA (&gt;1:40) were significantly associated with biochemical (76.9% and 79.8%) and histological features (100% and 100%) of disease activity (<\/jats:bold>\n                                 <jats:bold>\n                                    P\n                                 <\/jats:bold>\n                                 <jats:bold>&lt; 0.001).<\/jats:bold>\n                                 <jats:bold>\n                                    Conclusion\n                                 <\/jats:bold>\n                                 <jats:bold>: With the exception of ANA, the autoantibody profile does not markedly vary in the course of AIH. The persistence of high titers of ASMA and\/or AAA in patients with AIH is associated with disease activity. (Hepatology 2014;59:592\u2013600)<\/jats:bold>\n                              <\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/hep.26666","type":"journal-article","created":{"date-parts":[[2013,8,8]],"date-time":"2013-08-08T15:10:46Z","timestamp":1375974646000},"page":"592-600","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":81,"title":["Antismooth Muscle and Antiactin Antibodies Are Indirect Markers of Histological and Biochemical Activity of Autoimmune Hepatitis"],"prefix":"10.1097","volume":"59","author":[{"given":"Claudia A.","family":"Couto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo L.","family":"Bittencourt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilda","family":"Porta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarice P.","family":"Abrantes-Lemos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flair J.","family":"Carrilho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca D.","family":"Guardia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo L.R.","family":"Can\u00e7ado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-26-20250207","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMra050408","article-title":"Autoimmune hepatitis.","volume":"354","author":"Krawitt","year":"2006","journal-title":"N Engl J Med"},{"key":"R2-26-20250207","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1053\/jhep.2002.34944","article-title":"Diagnosis and treatment of autoimmune hepatitis.","volume":"36","author":"Czaja","year":"2002","journal-title":"Hepatology"},{"key":"R3-26-20250207","doi-asserted-by":"crossref","first-page":"23S26S","DOI":"10.1016\/0002-9343(94)90186-4","article-title":"Autoimmune hepatitis: classification, heterogeneity, and treatment.","volume":"96","author":"Krawitt","year":"1994","journal-title":"Am J Med"},{"key":"R4-26-20250207","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.jhep.2004.08.002","article-title":"Liver autoimmune serology: a consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group.","volume":"41","author":"Vergani","year":"2004","journal-title":"J Hepatol"},{"key":"R5-26-20250207","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S0140-6736(87)92024-1","article-title":"Characterisation of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen.","volume":"1","author":"Manns","year":"1987","journal-title":"Lancet"},{"key":"R6-26-20250207","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S0168-8278(00)80361-X","article-title":"Antibodies to soluble liver antigen: an additional marker in type 1 autoimmune hepatitis.","volume":"33","author":"Ballot","year":"2000","journal-title":"J Hepatol"},{"key":"R7-26-20250207","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1136\/gut.51.2.259","article-title":"Establishment of standardised SLALP immunoassays: specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics.","volume":"51","author":"Baeres","year":"2002","journal-title":"Gut"},{"key":"R8-26-20250207","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1080\/0891693021000056721","article-title":"Organ and nonorgan specific autoantibody titres and IgG levels as markers of disease activity: a longitudinal study in childhood autoimmune liver disease.","volume":"35","author":"Gregorio","year":"2002","journal-title":"Autoimmunity"},{"key":"R9-26-20250207","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/S0168-8278(99)80096-8","article-title":"Behavior and significance of autoantibodies in type 1 autoimmune hepatitis.","volume":"30","author":"Czaja","year":"1999","journal-title":"J Hepatol"},{"key":"R10-26-20250207","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1002\/hep.510240515","article-title":"Frequency and significance of antibodies to actin in type 1 autoimmune hepatitis.","volume":"24","author":"Czaja","year":"1996","journal-title":"Hepatology"},{"key":"R11-26-20250207","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1053\/jhep.2002.32092","article-title":"Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease.","volume":"35","author":"Ma","year":"2002","journal-title":"Hepatology"},{"key":"R12-26-20250207","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1572-0241.2002.05479.x","article-title":"Antibodies to soluble liver antigenliver pancreas and HLA risk factors for type 1 autoimmune hepatitis.","volume":"97","author":"Czaja","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"R13-26-20250207","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/hep.1840070626","article-title":"Chronic active hepatitis associated with antiliverkidney microsome antibody type 1: a second type of autoimmune hepatitis.","volume":"7","author":"Homberg","year":"1987","journal-title":"Hepatology"},{"key":"R14-26-20250207","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1136\/gut.42.5.721","article-title":"Liverkidney microsomal antibody type 1 and liver cytosol antibody type 1 concentrations in type 2 autoimmune hepatitis.","volume":"42","author":"Muratori","year":"1998","journal-title":"Gut"},{"key":"R15-26-20250207","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0168-8278(99)80297-9","article-title":"International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis.","volume":"31","author":"Alvarez","year":"1999","journal-title":"J Hepatol"},{"key":"R16-26-20250207","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1006\/jaut.2001.0540","article-title":"Thermolabile and calciumdependent serum factor interferes with polymerized actin, and impairs antiactin antibody detection.","volume":"17","author":"Cancado","year":"2001","journal-title":"J Autoimmun"},{"key":"R17-26-20250207","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/j.1432-1033.1979.tb04204.x","article-title":"FActindepolymerizing activity of human serum.","volume":"100","author":"Norberg","year":"1979","journal-title":"Eur J Biochem"},{"key":"R18-26-20250207","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1084\/jem.161.5.1231","article-title":"Antiliverkidney microsome antibody recognizes a 50,000 molecular weight protein of the endoplasmic reticulum.","volume":"161","author":"Alvarez","year":"1985","journal-title":"J Exp Med"},{"key":"R19-26-20250207","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1002\/hep.23584","article-title":"American Association for the Study of Liver Diseases. Diagnosis and management of autoimmune hepatitis.","volume":"51","author":"Manns","year":"2010","journal-title":"Hepatology"},{"key":"R20-26-20250207","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1002\/hep.1840180435","article-title":"Meeting report: International Autoimmune Hepatitis Group.","volume":"18","author":"Johnson","year":"1993","journal-title":"Hepatology"},{"key":"R21-26-20250207","first-page":"137","article-title":"LCC, SBPSBH C. Visao historica e consenso nacional sobre a classificacao das hepatites cronicas.","volume":"19","year":"2000","journal-title":"GED"},{"key":"R22-26-20250207","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1002\/hep.1840190629","article-title":"Classification of chronic hepatitis: diagnosis, grading and staging.","volume":"19","author":"Desmet","year":"1994","journal-title":"Hepatology"},{"key":"R23-26-20250207","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1872-034X.2008.00454.x","article-title":"Clinical features of type 1 autoimmune hepatitis in adolescence and early adulthood.","volume":"39","author":"Miyake","year":"2009","journal-title":"Hepatol Res"},{"key":"R24-26-20250207","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.cgh.2008.08.043","article-title":"Serologic markers do not predict histologic severity or response to treatment in patients with autoimmune hepatitis.","volume":"7","author":"Mehendiratta","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R25-26-20250207","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/hep.510260305","article-title":"Serum autoantibodies in chronic hepatitis C: comparison with autoimmune hepatitis and impact on the disease profile.","volume":"26","author":"Cassani","year":"1997","journal-title":"Hepatology"},{"key":"R26-26-20250207","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s12072-011-9277-8","article-title":"Clinical significance of serum autoantibodies in patients with NAFLD: results from the nonalcoholic steatohepatitis clinical research network.","volume":"6","author":"Vuppalanchi","year":"2012","journal-title":"Hepatol Int"},{"key":"R27-26-20250207","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1136\/jcp.2005.027367","article-title":"Antibodies to filamentous actin (Factin) in type 1 autoimmune hepatitis.","volume":"59","author":"Granito","year":"2006","journal-title":"J Clin Pathol"},{"key":"R28-26-20250207","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1111\/j.1572-0241.1999.01229.x","article-title":"Genetic heterogeneity in susceptibility to autoimmune hepatitis types 1 and 2.","volume":"94","author":"Bittencourt","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"R29-26-20250207","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/S0168-8278(02)00182-4","article-title":"Clinical distinctions and pathogenic implications of type 1 autoimmune hepatitis in Brazil and the United States.","volume":"37","author":"Czaja","year":"2002","journal-title":"J Hepatol"},{"key":"R30-26-20250207","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1053\/jhep.2001.22131","article-title":"Autoimmune hepatitissclerosing cholangitis overlap syndrome in childhood: a 16year prospective study.","volume":"33","author":"Gregorio","year":"2001","journal-title":"Hepatology"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.26666","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-201402000-00026","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T16:49:47Z","timestamp":1738946987000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-201402000-00026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.26666","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]}}}